| 1 |
33875937 | YM155 inhibits retinal pigment epithelium cell survival through EGFR/MAPK signaling pathway. | 2021 |
5 |
| 2 |
32001757 | Identification of synergistic drug combinations using breast cancer patient-derived xenografts. | 2020 Jan 30 |
1 |
| 3 |
32638093 | Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer. | 2020 Aug |
1 |
| 4 |
29413056 | EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. | 2018 Feb |
1 |
| 5 |
30315932 | YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction. | 2018 Dec |
5 |
| 6 |
28787001 | YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. | 2017 |
3 |
| 7 |
23325792 | YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. | 2013 Mar |
3 |
| 8 |
22723871 | YM155 induces EGFR suppression in pancreatic cancer cells. | 2012 |
1 |